Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc.

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen’s latest psoriasis study update spotlights apremilast (AMG 407) for ki...

Amgen’s Pediatric Psoriasis Study Wrap-Up: What Apremilast Safety Data Means for Investors

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has started a new Phase 1 trial called “A Phase 1, Open-La...

Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. is moving ahead with MARITIME-2-EXTENSION, a Phase 3 trial that t...

Amgen Extends MariTide Study In Obesity And Diabetes, Keeping Investor Focus On Long-Term Potential

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen’s new Phase 3 DeLLphi-315 study tests its cancer drug tarlatamab in pe...

Amgen Advances Tarlatamab Shot vs. Infusion in Phase 3 Lung Cancer Study

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGN) and CVS Health (CVS) with bullish senti...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and CVS Health (CVS)

U.S. stocks ended another positive week near record highs, although Friday’s weak retail sales report took some of the shine off the rally. The S&P...

The Week That Was, The Week Ahead: Macro and Markets, August 16

Insiders have been trading these 5 stocks: (($AMGN)), (($CEG)), (($FSLY)), (($KEEL)) and (($BX)). Here is a breakdown of their recent trades and th...

Amgen, Constellation, Fastly, Keel & Blackstone Shock Wall St.

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) is launching a new Phase 2/3 study called “A Trial of Ineb...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AMGN	$437.23	-1.55%	1.66M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AMGN	$437.23	-1.6%	1.66M
3
4
5
6

AMGN

Get Amgen Inc. Data in Excel

Get Amgen Inc. Data in Excel